World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE
LIVE IN-PERSON ON-LINE
December 2–4, 2021

Exploring New Frontiers In Metabolism – Tomorrow’s Clinical Science Today
Welcome.

It is my pleasure to invite you to the 19th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism—Tomorrow’s Clinical Science Today.

We are excited to announce that the 19th Annual WCIRDC returns live in person to the Hilton Universal City, Los Angeles. Based on last year’s incredible success we continue to offer virtual participation—Live Online and On-Demand for 3 months, to accommodate our attendees from across the globe.

Since its inception, the congress has become the premier global meeting dedicated to metabolism-obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates both clinical and basic science. It offers an exclusive opportunity for professionals, researchers, and other clinicians to collaborate on emerging scientific and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside-to-bench approach that is unique to this state-of-the-art program.

During the 19th WCIRDC, we will honor Drs. Christos Mantzoros and Samuel Klein, the recipients of the 2020 and 2021 Gerald Reaven Distinguished Leader in Insulin Resistance Award. This year’s conference will cover a wide range of topics including the most up-to-date CV outcome trials, research in - and management recommendations for- Obesity, Diabetes insulin resistance, COVID-19, dyslipidemia, NAFLD & NASH, ASCVD, heart failure, CKD, CardioRenalMetabolism in youth, hormones and atherosclerosis and much more.

Highlights of the conference will be: a special session-first time ever: Multispecialty — Management of Diabetes, Cardiorenal & Metabolic Diseases — Practice Recommendations 2022; Diabetes — Past, Present & Future; CVD, HF and ASCVD in patients with & without Diabetes; a Joint session with the Journal Metabolism; A Glimpse in the Future — What’s in the Pipeline? Has the Beta Cell Been Forgotten?

Live in-person attendees will be able to participate in clinical workshops, meet the expert sessions and have an opportunity to personally interact and meet, in an intimate setting, the world’s top professionals, experts, and most esteemed leaders in their respective fields.

The 19th WCIRDC congress will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and Industry Supported non-CME programs that will feature important new scientific concepts with some the world’s best-known educators of their fields.

I look forward to you joining this exciting conference on December 2–4, 2021, in Los Angeles.

Best regards,

Yehuda Handelsman, MD
Chair & Program Director

Yehuda Handelsman, MD Chair Tarzana, CA Richard N. Bergman, PhD Los Angeles, CA Zachary T. Bloomgarden, MD New York, NY Matthew J. Budoff, MD Los Angeles, CA Sonia Caprio, MD New Haven, CT Robert J. Chilton, DO San Antonio, TX Kenneth Cusi, MD Gainesville, FL Jaime A. Davidson, MD Dallas, TX Ralph A. DeFronzo, MD San Antonio, TX Daniel Einhorn, MD La Jolla, CA Vivian A. Fonseca, MD New Orleans, LA W. Timothy Garvey, MD Birmingham, AL Peter J. Grant, MD Leeds, United Kingdom Jennifer Green, MD Durham, North Carolina George Grunberger, MD Bloomfield Hills, MI Chris K. Guerin, MD Oceanside, CA Paul S. Jellinger, MD Hollywood, FL Samuel Klein, MD St. Louis, MO Mikhail N. Kosiborod, MD Kansas City, MO Ronald M. Krauss, MD Berkeley, CA Norman Lepor, MD Los Angeles, CA Derek LeRoith, MD, PhD New York, NY Philip Levy, MD Phoenix, AZ Christos Mantzoros, MD, PhD Boston, MA Nikolaus Marx, MD Aachen, Germany Tracey L. McLaughlin, MD Stanford, CA Christian W. Mende, MD La Jolla, CA Jorge Plutzky, MD Boston, MA Richard Pratley, MD Orlando, FL Arun J. Sanyal, MD Richmond, VA Philipp E. Scherer, PhD Dallas, TX Alan R. Sinaiko, MD Minneapolis, MN Bart Staels, PhD Lille, France Pam R. Taub, MD San Diego, CA Murthiala Vagunanathan, MD, MPH Boston, MA Matthew R. Weir, MD Baltimore, MD Paul Zimmet, AO, PhD Melbourne, Australia
PROGRAM DESCRIPTION

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 19th year, is a unique and exciting multidisciplinary CME conference. The Congress has become the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

WCIRDC 2021 will return to Live in Person meeting at the Hilton Universal City Hotel in Los Angeles, on December 2-4, 2021. The conference will also have a virtual component—Streaming Live online followed by 90 days On Demand.

In this CME meeting participants can earn up to 24 CME & ABIM-MOC credits.

WCIRDC is the only meeting of its size combining basic and clinical science. For nearly two decades it has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside— to-bench. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty. In an intimate setting, for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, obesity, CVD, the Congress’ focus has expanded to cover the kidney, liver, brain, bone, cancer, and more. The congress addresses dyslipidemia, atherosclerosis, hypertension, hypercoagulation, inflammation, and energy metabolism. It provides the newest clinical updates on pharmaceutical interventions such as GLP1ra, SGLT2i’s, PCSK9i’s, MRA and EPA to name a few. The goal is to understand the state-of-the-art pathophysiology, new medical interventions, and to develop appropriate comprehensive clinical management strategies.

To make basic and clinical research topics relevant to clinical medicine, following each session there will be live Q&A and a discussion on implications to clinical practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of live panel, providing summary of the day, commentary, and open for Q&A.

The Congress attracts state-of-the-art abstracts attracting, young up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be published in Metabolism, a peer-reviewed journal and also available for 90 days on demand.

The congress is featured by many media outlets with proceedings featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes and its complications and others.

PROGRAM OBJECTIVES

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions; focusing on basic science such as insulin resistance, fat cells, inflammation, and on clinical practice; understanding the comprehensive management cardiorenalmetabolic conditions.

Upon completion of this meeting, participants should be able to:

- Discuss COVID-19 in diabetes and Obesity.
- Describe the relationship between diabetes, obesity, and heart failure
- Discuss T1D obesity and CVD
- Discuss the role of the beta cells in diabetes
- Discuss the role of fat cells in the development of cardiometabolic conditions
- Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes
- Provide the traditional comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia.
- Highlight the paradigm shift in management focusing on preventing the next event of ASCVD, HF and CKD
- Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD.
- Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD
- Address SGLT2i role in managing patients with CKD and HF-ED & HFpEF
- Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- Discuss fatty liver disease and its relationship to diabetes and CVD
- Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
- Technology in monitoring and reducing DM & ASCVD
- Address the multispecialty practice recommendations to managing patients with cardiorenalmetabolic diseases

TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYN, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.
PROGRAM 2021

7:00 am - 8:00 am EXHIBIT HALL OPEN
8:00 am - 8:15 am Welcome & Introduction | Pre-CME Questions

SESSION 1  Has the Beta Cell Been Forgotten?
Chair: Ralph DeFronzo, MD
8:15 am - 9:50 am Panel Discussion and Q&A

SESSION 2  COVID-19 in CardioRenalMetabolism
Chairs: Chris Guerin, MD • Christian W. Mende, MD
9:50 am - 10:35 am Panel Discussion and Q&A

10:50 – 11:20 am REFRESHMENT BREAK

11:20 am – 12:10 pm Concurrent Sessions MEET THE EXPERTS (In-Person Only)

Daniel Einhorn, MD  Cortisol & Metabolism  Sierra C/D
Ralph DeFronzo, MD  Everything Insulin Resistance  Club Room
Matthew Budoff, MD  ASCVD Diagnosis Management  Hiro Room
Yehuda Handelsman, MD  DM & the Heart A Paradigm Shift  Salon 6AB

12:15 pm – 1:15 pm LUNCH BREAK

SESSION 3  The Liver: NAFLD & NASH
Chairs: Jennifer Green, MD • Daniel Einhorn, MD
1:15 pm - 1:55 pm Panel Discussion and Q&A
SESSION 4  CardioRenalMetabolism in Youth
Chairs: Alan R. Sinaiko, MD • Sonia Caprio, MD

2:10 pm  Value of Early Lipid-Lowering Interventions to Prevent Later Life Cardiovascular Disease  Andrew Moran, MD, MPH
2:25 pm  Co-existence of Prediabetes and Non-Alcoholic Fatty Liver Disease in Pediatric Obesity  Sonia Caprio, MD
2:40 pm  Long-term complications in youth-onset type 2 diabetes: the TODAY study  Phil Zeitler, MD, PhD
2:55 pm – 3:15 pm  Panel Discussion and Q&A

3:15 pm – 3:45 pm  REFRESHMENT BREAK

SESSION 5  Diabetes – Special Populations
Chairs: Zachary Bloomgarden, MD • Tracey L. McLaughlin, MD

3:45 pm  LADA: Epidemiology similarities & differences from T2D/T1D – Impact on Comorbidities  Richard E. Pratley, MD
4:05 pm  C-peptide Levels and CVD Outcomes in the VADT  Peter Reaven, MD
4:25 pm – 4:35 pm  Panel Discussion and Q&A

SESSION 6  Dyslipidemia & ASCVD
Chairs: Paul S. Jellinger, MD • Matthew J. Budoff, MD

4:35 pm  Beyond LDL-C: The Role of Dyslipidemia in ASCVD  Ron M. Krauss, MD
4:55 pm  Novel Agents and Combination Therapy in Management of Dyslipidemia  Erin D. Michos, MD
5:15 pm – 5:30 pm  Panel Discussion and Q&A

5:30 pm – 6:30 pm  DAY 1 SUMMARY SESSION & POST-CME QUESTIONS
Sonia Caprio, MD • Ralph A. DeFronzo, MD • Jennifer Green, MD • Yehuda Handelsman, MD • Ronald M. Krauss, MD • Tracey L. McLaughlin, MD

6:30 pm – 7:30 pm  WELCOME AND POSTER RECEPTION

7:30 pm – 8:30 pm  Dinner Session  Non-CME  Product Theater Hall
An Overview of the FreeStyle Libre 2 System  Supported by: Abbott  George Grunberger, MD

FRIDAY, DECEMBER 3, 2021

7:00 am – 8:00 am  EXHIBIT HALL OPEN | Continental Breakfast
8:00 am – 8:10 am  Pre-CME Questions
SESSION 7  Metabolism & WCIRDC – Joint Session
Chair: Michael A. Hill, PhD • Yehuda Handelsman, MD

8:10 am  Insulin Action / Insulin Resistance / Diabetes and the Heart  Dale Abel, MD, PhD
8:25 am  Cardiovascular Actions and Therapeutic Potential of Novel Anti-Diabetic Agents  Michael A. Hill, PhD
8:40 am  Drug Development for Cardiometabolic Disorders - Focusing on the Patient  Theodoros Kelesidis, MD, PhD
8:55 am – 9:10 am  Panel Discussion and Q&A
### SESSION 8  
**Hormones, Cytokine, & Insulin – Role in Morbidities**  
Chairs: Richard N. Bergman, PhD • Samuel Klein, MD  

- **9:10 am** Insulin Action and Insulin Resistance in the Kidney  
  Gerald I. Shulman, MD, PhD
- **9:25 am** FGF1 and Insulin Control Adipose Lipolysis by Convergent Pathways  
  Ronald M. Evans, PhD
- **9:40 am** Adiponectin & Leptin Roles in Cardiometabolic Control, Diabetes, Aging and Mortality  
  Philipp E. Scherer, PhD
- **9:55 am – 10:15 am** Panel Discussion and Q&A

**10:15 am – 10:45 am** REFRESHMENT BREAK

### SESSION 9  
**Pumps, CGM, Risk Engine and Hypoglycemia**  
Chairs: Richard E. Pratley, MD • W. Timothy Garvey, MD  

- **10:45 am** BRAVO risk Engine – Simulating Trials and Evaluating Cost  
  Vivian A. Fonseca, MD
- **11:00 am** Clinical Guidelines 2021 - CGM and Insulin Pump Therapy  
  George Grunberger, MD
- **11:15 am** Hypoglycemia Contemporary approach to management  
  Guillermo Umpierrez, MD
- **11:30 am – 11:45 am** Panel Discussion and Q&A

### SESSION 10  
**A Glimpse in the Future - What's in the Pipeline? (Non-CME)**  
Chairs: Ralph DeFronzo, MD • Tracey L. McLaughlin, MD  

- **11:45 am** Zealand  
  David Kendall, MD
- **12:00 pm** Boehringer Ingelheim  
  Mohamed Eid, MD, MPH, MHA
- **12:15 pm** Corcept  
  Joe Belanoff, MD
- **12:30 pm** Regeneron  
  Sergio Fazio, MD, PhD
- **12:45 pm – 1:00 pm** Panel Discussion and Q&A

**1:00 pm – 2:00 pm** LUNCH BREAK

**1:10 pm – 1:55 pm** Lunch Session Non-CME  
Primary Hypercortisolism: What are We Missing and Why Does it Matter?  
Supported by: Corcept Therapeutics  
Daniel Einhorn, MD

### SESSION 11  
**Multispecialty – Management of Diabetes, Cardio Renal & Metabolic Diseases – Practice Recommendations**  
Chair: Yehuda Handelsman, MD  

- **2:00 pm** Matthew Budoff, MD • Daniel Einhorn, MD • Vivian Fonseca, MD • Jennifer Green, MD • George Grunberger, MD • Christian Mende, MD • Erin D. Michos, MD
- **3:00 pm – 3:30 pm** Panel Discussion and Q&A

**3:30 pm – 4:00 pm** REFRESHMENT BREAK

### SESSION 12  
**The Heart, Metabolism and CVOT**  
Chairs: Peter J. Grant, MD • Norman E. Lepor, MD  

- **4:00 pm** Aortic Stenosis and Metabolic Diseases  
  Robert J. Chilton, DO
- **4:15 pm** Testosterone Treatment Impact on Atherosclerosis in Men  
  Matthew J. Budoff, MD
- **4:30 pm** Impact of Hormones on Cardiometabolic Health  
  Pam R. Taub, MD
- **4:45 pm** Update on CVOTs  
  Mikhail N. Kosiborod, MD
- **5:10 pm – 5:30 pm** Panel Discussion and Q&A
FRIDAY, DECEMBER 3, 2021 (cont.)

5:30 pm – 6:30 pm  DAY 2 SUMMARY SESSION & POST-CME QUESTIONS
Ralph DeFronzo, MD • Yehuda Handelsman, MD • Samuel Klein, MD
Mikhail N. Kosiborod, MD • Norman E. Lepor, MD • Richard E. Pratley, MD

6:30 pm – 7:30 pm  Dinner Session  Non-CME
Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C
Supported by: Esperion Therapeutics

7:30 pm – 9:00 pm  ABSTRACT ORAL PRESENTATION  Sierra C/D  Cheese & Wine
Zachary Bloomgarden, MD, Chair
Abstract Committee: Daniel Einhorn, MD • George Grunberger, MD • Philip Levy, MD
Abstracts are published in Metabolism  Editor-in-Chief: Christos S. Mantzoros, MD, PhD

SATURDAY, DECEMBER 4, 2021

7:00 am – 8:00 am  Continental Breakfast

7:00 am – 7:45 am  Morning Session  Non-CME
Clinical Utility of Glycated Albumin & Validation Studies as an Intermediate Glycemic Control Marker
Supported by: Asahi Kasei Pharma Corporation

8:00 am – 8:05 am  Abstract Oral Winner Presentation
8:05 am – 8:15 am  Pre-CME Questions

SESSION 13 Diabetes – Past, Present & Future
Chairs: George Grunberger, MD • Vivian A. Fonseca, MD

8:15 am  Insulin - 100 years of Progress  Jay S. Skyler, MD
8:30 am  The Importance of Long Term Management of Hyperglycemia  Peter J. Grant, MD
8:45 am  Early Combination Therapy in DM - Impact on Comorbidities  Jennifer Green, MD
9:00 am  Reversing Type 2 Diabetes from Day One  Julio Rosenstock, MD
9:15 am – 9:35 am  Panel Discussion and Q&A

SESSION 14 Obesity 2021 – A Paradigm Shift
Chairs: Ronald M. Krauss, MD • Matthew R. Weir, MD

9:35 am  A New Era in Obesity Medicine: Treat-to-Target  W. Timothy Garvey, MD
9:50 am  What’s the Best Weight Loss Diet?  Donna H. Ryan, MD
10:05 am  Key Concepts in Treating Obesity as a Disease: A Focus on Pharmacological Interventions  Ania Jastreboff, MD, PhD

10:20 am -10:35 am  REFRESHMENT BREAK
GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE – 2021 AWARD

10:35 am  2021 Award Presentation “Gerald Reaven Distinguished Leader in Insulin Resistance”
10:40 am  Why Does Obesity Cause Type 2 Diabetes

Samuel Klein, MD

11:10 am – 11:30 am  Session 14 Panel Discussion and Q&A

11:30 am – 12:30 pm  LUNCH BREAK

11:40 am – 12:25 pm  Lunch Session  Non-CME  Product Theater Hall
The Role of the Gut in Type 2 Diabetes: Going Beyond Incretins
Supported by: Fractyl Health

Geltrude Mingrone, MD, PhD  Randy Seeley, PhD

SESSION 15  Glucose Metabolism and Diabetes
Chairs: Philipp E. Scherer, PhD • Richard N. Bergman, PhD

12:30 pm  Insulin Resistance Impact on Insulin Clearance and Metabolic Demand Effect on Glucose Tolerance
Ralph DeFronzo, MD
12:45 pm  Statin Associated with Increased Insulin Resistance & Diabetes
Joshua W. Knowles, MD
1:00 pm – 1:10 pm  Panel Discussion and Q&A

SESSION 16  CKD, HF and ASCVD in Diabetes & Without
Chairs: Pam R. Taub, MD • Peter J. Grant, MD

1:10 pm  The Role of (Micro) Albuminuria in Predicting HF, ASCVD and CKD
Richard E. Pratley, MD
1:25 pm  The Prevention of ASCVD in Patients with Diabetes
Ildiko Lingvay, MD
1:40 pm  Update in HF Management — How Should/Would the Guidelines Look?
Mikhail N. Kosiborod, MD

1:55 pm – 2:10 pm  REFRESHMENT BREAK

2:10 pm  Heart Failure today: A new epidemic or a co-morbidity
Mark Kearney, MD
2:25 pm  The Contemporary Approach to MRA, Aldosterone in the Kidney and the Heart
Christian W. Mende, MD
2:40 pm  Treatment of Diabetic Nephropathy: what does the future hold?
Robert D. Toto, MD
2:55 pm – 3:15 pm  Panel Discussion and Q&A

3:15 pm – 4:10 pm  DAY 3 SUMMARY SESSION & POST-CME QUESTIONS
Richard N. Bergman, PhD • W. Timothy Garvey, MD • Peter J. Grant, MD
George Grunberger, MD • Yehuda Handelsman, MD • Pam R. Taub, MD

4:15 pm – 5:00 pm  Concurrent Sessions  CLINICAL WORKSHOPS  (In-Person Only)

Management of DM  Sierra Ballroom C/D  Yehuda Handelsman, MD
All You Wanted to Know about CGM  Sierra Ballroom B  George Grunberger, MD
Lipids  Club Room  Paul Jellinger, MD • Paul Rosenblit, MD
Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE  
Medical Director & Principal Investigator  
The Metabolic Institute of America  
Chair & Program Director  
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)  
Chair & Founder  
International Committee for Insulin Resistance  
Tarzana, California

Muhammad Abdul-Ghani, MD, PhD  
Professor of Medicine, Division of Diabetes  
University of Texas Health Science Center at San Antonio  
San Antonio, TX

Dale Abel, MD, PhD  
Professor & Head  
Internal Medicine  
University of Iowa Carver College of Medicine  
Iowa City, Iowa

Joseph K. Belanoff, MD  
Chief Executive Officer, President and Director  
Concept Therapeutics

Richard N. Bergman, PhD  
Alfred Joy Frienstein Chair in Diabetes Research Professor  
Department of Biomedical Sciences  
Cedars-Sinai Director  
Sports Spectacular Diabetes and Obesity Wellness and Research Center (SSDOWRC)  
Professor-in-Residence, Department of Medicine, UCLA  
Los Angeles, California

Zachary T. Bloomgarden, MD, MACE  
Clinical Professor Department of Medicine  
Ichan School of Medicine at Mount Sinai  
Editor, The Journal of Diabetes  
New York, New York

Matthew J. Budoff, MD  
FACC, FAHA  
Professor of Medicine  
David Geffen School of Medicine at UCLA  
Endowed Chair of Preventive Cardiology  
Program Director, Director of Cardiac CT  
Lundquist Institute  
Harbor-UCLA Medical Center  
Division of Cardiology  
Los Angeles, California

Sonia Caprio, MD  
Professor of Pediatric Endocrinology  
Yale University School of Medicine  
New Haven, Connecticut

Robert J. Chilton, DO, FACP, FACC, FAHA  
Professor of Medicine  
Department of Medicine  
Division of Cardiology  
The University of Texas Health Science Center  
San Antonio, Texas

Ralph A. DeFronzo, MD  
Professor of Medicine Chief  
Diabetes Division  
University of Texas Health Science Center  
San Antonio, Texas

Mohamed A. Eid, MD MPH, MHA  
Head of Clinical Development & Medical Affairs  
Cardio-Renal-Metabolism & Respiratory Medicine  
Boehringer Ingelheim Pharmaceuticals Inc.  
Ridgefield, Connecticut

Daniel Einhorn, MD, FACP, FACE  
Chief, Diabetes and Endocrine Associates  
Medical Director  
Scraps Whittier Diabetes Institute  
Clinical Professor, UCSD School of Medicine  
La Jolla, California

Ronald M. Evans, PhD  
Professor and Director  
Gene Expression Laboratory  
March of Dimes Chair in Molecular and Developmental Biology  
La Jolla, California

Michael E. Farkouh, MD, MSc, FRCP, FACC, FAHA  
Peter Munk Chair in Multinational Clinical Trials  
Director, Heart & Stroke Richard Lewar Centre of Excellence  
Vice-Chair Research & Professor of Medicine  
Department of Medicine  
University of Toronto  
Toronto, Ontario, Canada

Sergio Fazio, MD, PhD  
Chair, Scientific Council - CV/Metabolic  
Regeneron Pharmaceuticals  
New York, New York

Vivian A. Fonseca, MD, FRCP  
Professor of Medicine and Pharmacology  
Assistant Dean for Clinical Research  
Tulis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology  
Tulane University Health Sciences Center  
New Orleans, Louisiana

W. Timothy Garvey, MD  
Butterworth Professor  
Department of Nutrition Sciences  
University of Alabama at Birmingham  
Director, UAB Diabetes Research Center  
Birmingham, Alabama

Peter J. Grant, MD  
FRCP, FMedSci  
Professor of Medicine  
Honorary Consultant Physician  
University of Leeds  
Leeds Teaching Hospitals NHS Trust  
Division of Cardiovascular & Diabetes Research  
LIGHT Laboratories  
Leeds, United Kingdom

Jennifer Green, MD  
Professor of Medicine  
Duke University Medical Center  
Division of Endocrinology  
Duke Clinical Research Institute  
Durham, North Carolina
FACULTY 2021

George Grunberger, MD
FACP, MACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine
Charles University, Prague, Czech Republic
Bloomfield Hills, Michigan

Chris K. Guerin, MD
Chief, Division of Endocrinology and Metabolism
Tri-City Medical Center at Oceanside, California
Founder-Advanced Metabolic Care and Research
Voluntary Assistant Clinical Professor
University of California at San Diego
Chair Past President’s Committee for CACE and Board of Directors
San Diego, California

Michael A. Hill, PhD
Interim Director, Dalton Cardiovascular Research Center
Professor, Department of Medical Pharmacology and Physiology,
School of Medicine
University of Missouri Columbia, Missouri

Ania Jastreboff, MD, PhD
Associate Professor
Director, Weight Management & Obesity Prevention
Medical Director, Yale Stress Center
New Haven, Connecticut

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty University of Miami, Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Steven E. Kahn, MD
Division of Metabolism
Endocrinology and Nutrition
Department of Medicine
VA Puget Sound Health Care System
University of Washington
Seattle, Washington

Mark Kearney, MD
MBChB, MRCP
British Heart Foundation Professor of Cardiovascular and Diabetes Research
Leeds Institute of Cardiovascular & Metabolic Medicine
Dean of the School of Medicine
University of Leeds
Leeds, United Kingdom

Theodoros Kelesidis, MD, PhD
Associate Professor
Department of Medicine
Division of Infectious Diseases
David Geffen School of Medicine at UCLA
Encina, California

David Kendall, MD
Sr. Global Medical Advisor
Zealand Pharma
Westlake Village, California

Samuel Klein, MD
Director, Center for Human Nutrition
Chief Scientific Officer, Sansum Diabetes Research Institute
Washington University School of Medicine
Saint Louis, Missouri

Joshua W. Knowles, MD, PhD
Assistant Professor, Cardiovascular Medicine
Stanford University
Attending Physician, Stanford Center for Inherited Cardiovascular Disease
Director, Familial Hypercholesterolemia (FH) Clinic
Program Director, Stanford Cardiovascular Medicine Fellowship Program
Co-director, Stanford Translational Investigator Program
Stanford, California

Mikhail N. Kosiborod MD
FACC, FAHA
Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Kansas City, Missouri

Ronald M. Krauss, MD
Senior Scientist and Director
Atherosclerosis Research
Children’s Hospital Oakland Research Institute
Adjunct Professor
Department of Medicine, UCSF
Adjunct Professor
Department of Nutritional Sciences
University of California, Berkeley
Berkeley, California

Rohit Kulkarni, MD, PhD
Islet Cell and Regenerative Biology
Co-Section Head and Senior Investigator
Joslin Diabetes Center, Department of Medicine
Brigham and Women’s Hospital
Harvard Stem Cell Institute
Harvard Medical School
Boston, Massachusetts

John Leahy, MD
Professor Emeritus, Department of Medicine
Division of Endocrinology
Diabetes and Metabolism
Colchester, Vermont

Norman E. Lepor, MD
FACC, FAHA, FSCAI
Clinical Professor of Medicine Geffen/UCLA School of Medicine
Smiti Cedars-Sinai Heart Institute
Westside Medical Associates of Los Angeles
Los Angeles, California

Philip Levy, MD, MACE
Clinical Professor of Medicine
University of Arizona College of Medicine
Endocrinologist
Banner University Medical Group
Phoenix, Arizona
Ildiko Lingvay, MD
MPH, MSCS
Professor of Medicine
Department of Internal Medicine
Division of Endocrinology and
Department of Population and Data Sciences
Medical Director
Office of Clinical Trial Management
University of Texas Southwestern Medical Center
Dallas, Texas

Christos S. Mantzoros, MD
DSc, PhD h.c. mult.
Professor of Medicine
Harvard Medical School and
Boston University School of Medicine
Chief of Endocrinology
Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism,
Clinical & Experimental
Boston, Massachusetts

Tracey L. McLaughlin, MD, MS
Professor of Medicine
Division of Endocrinology
Stanford University School of Medicine
Stanford, California

Christian W. Mende, MD
FACP, FACC, FASN, FASH
Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Erin D. Michos, MD, MHS
FAHA, FACC, FASE, FASPC
Associate Professor of Medicine (Cardiology) and Epidemiology
Associate Director of Preventive Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrew Moran, MD, MPH
Director, Global Hypertension Control
Resolve to Save Lives
Associate Professor of Medicine
Columbia University
New York, New York

Mazen Noureddin, MD
Director, Cedars-Sinai Fatty Liver Program
Los Angeles, California

Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida

Peter Reaven, MD
Professor of Clinical Medicine
University of Arizona
Phoenix, Arizona

Paul D. Rosenbliit MD
PhD, FACE, FNLA
Clinical Professor, Medicine
Division of Endocrinology
Diabetes Metabolism
University of California, Irvine (UCI)
School of Medicine
Co-Director, Diabetes Outpatient Clinic
UCI Medical Center, Orange, CA
Director, & Site Principal Investigator
Diabetes / Lipid Management & Research Center
Huntington Beach, California

Julio Rosenstock, MD
Director, Dallas Diabetes Research Center
Medical City Dallas
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
New Orleans, Louisiana

Philipp E. Scherer, PhD
Touchstone Diabetes Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Gerald I. Shulman, MD, PhD
George R. Cowgill Professor of Medicine (Endocrinology)
Professor of Medicine and Cellular & Molecular Physiology
Co-Director Yale Diabetes Research Center
Yale University School of Medicine
New Haven, Connecticut

Alan R. Sinaiko, MD
Professor, Department of Pediatrics
Division of Pediatric Nephrology
University of Minnesota Medical School
Minneapolis, Minnesota

Jay S. Skyler, MD, MACP
Professor of Medicine
Pediatrics and Psychology
Deputy Director, Diabetes Research Institute
University of Miami
Miami, Florida

Laurence Sperling, MD
FACC, FAHA, FACP, FASPC
Katz Professor in Preventive Cardiology
Founder, Emory Heart Disease Prevention
Professor of Global Health
Emory University
Atlanta, Georgia
FACULTY 2021

Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center Professor of Medicine UC San Diego Health System Division of Cardiovascular Medicine La Jolla, California

Robert D. Toto, MD
Professor of Internal Medicine Associate Dean Translational Science and Education University of Texas Southwestern Medical Center Dallas, Texas

Guillermo Umpierrez, MD, CDE
Professor of Medicine Division of Endocrinology, Metabolism, and Lipids Emory University Atlanta, Georgia

Matthew R. Weir, MD
Professor and Chief Division of Nephrology Department of Medicine University of Maryland School of Medicine Baltimore, Maryland

Phil Zeitler, MD, PhD
Medical Director, Children’s Hospital Colorado Clinical & Translational Research Center, Section Head, Endocrinology Aurora, Colorado

19TH WCIRDC PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Richard N. Bergman, PhD • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD
Sonia Caprio, MD • Robert J. Chilton, DO • Kenneth Cusi, MD • Jaime Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD
Vivian A. Fonseca, MD • W. Timothy Garvey, MD • Peter J. Grant, MD • Jennifer Green, MD • George Grunberger, MD
Chris K. Guerin, MD • Paul S. Jellinger, MD • Samuel Klein, MD • Mikhail N. Kosiborod, MD
Ronald M. Krauss, MD • Norman Lepor, MD • Derek LeRoith, MD, PhD • Philip Levy, MD • Christoph Mantzoros, MD, DSc
Nikolaus Marx, MD • Tracey L. McLaughlin, MD • Christian W. Mende, MD • Jorge Plutzky, MD • Richard E. Pratley, MD
Arun J. Sanyal, MD • Philipp E. Scherer, PhD • Bart Straels, PhD • Pam R. Taub, MD • Muthiah Vaduganathan, MD, MPH
Matthew R. Weir, MD • Paul Zimmet, AO, PhD • Renee S. Asp, BS

ACCOMMODATIONS

The 19th Annual World Congress on Insulin Resistance, Diabetes & CVD (WCIRDC) will be held at the prestigious Hilton Universal City Hotel. The majestic Hilton Hotel is situated on a high hill above the Los Angeles entertainment district, near Universal Studios Hollywood and City Walk. The hotel is located a block from the main entrance of Universal Studios Hollywood, and is also a 3.5-mile drive to Pantages Theatre for Broadway shows. This 24-story hotel offers upscale rooms with panoramic views of the Hollywood Hills and Universal Studios.

Hilton Universal City Hotel 555 Universal Hollywood Drive Universal City, CA 91608

To reserve a room at our special rate of $216 a night for conference participants and their guests visit https://www.wcir.org/accommodations

Guests can also call In-House Reservations Dept. at 818-623-1434 from 8:30am-5pm PST Please reference the group name: WCIRDC
CME ACCREDITATION
For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com. This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA DESIGNATION STATEMENT
PESI Inc. has designated this Other (Live and Internet Live) activity for a maximum of 24 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC POINTS WITH ABIM
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points 24.

INTERNATIONAL CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.

PHYSICIAN ASSISTANTS
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

NURSES
For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA NURSES
Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 19th WCIRDC for a total of 24 contact hours.

PHARMACISTS
For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE
The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours 24.

REGISTERED DIETITIANS
For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

SATISFACTORY COMPLETION FOR CREDITS
All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite or virtually live attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity.

ENDURING/ON-DEMAND CME ACTIVITY
This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA DESIGNATION STATEMENT
PESI Inc. has designated this Enduring activity for a maximum of 24 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available online at www.wcirdc.com from December 6, 2021 through March 4, 2022.

Cancellation Policy: A full refund will be given if written notice of cancellation is received by September 6, 2021. A $75 cancellation fee will be charged for cancellation between September 7, 2021 and November 2, 2021. After November 2, 2021 there will be NO REFUNDS - only registration transfer credit will be offered. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

All 19th WCIRDC participants must be vaccinated in order to attend the live in person meeting. For further information please contact info@tmioa.com.
ASSOCIATED ORGANIZATIONS

Premier Associated Organizations
- California Chapter of the American College of Cardiology (CAACC)
- Clinical Association of California Endocrinologists (CACE)
- Cardio Renal Society of America (CRSA)

Associated Organizations
- American Society of Endocrine Physician Assistants (ASEPA)
- Association of Diabetes Care & Education Specialists (ADCES)
- Endocrine Nurses Society (ENS)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- Italian Society of Endocrinology (SIE)
- Point of Care Network (POCN)
- World Obesity Federation

MEDIA PARTNERS

Premier Media Partners
- Metabolism (Elsevier)
- American Journal of Cardiology (Elsevier)
- American Journal of Managed Care (MJH Life Sciences)
- Endocrinology Network (MJH Life Sciences)
- HCPLive Network (MJH Life Sciences)
- Healio: Cardiology Today & Endocrine Today
- Practical Cardiology (MJH Life Sciences)
- The Lancet Diabetes & Endocrinology

Media Partners
- Cardiovascular Endocrinology & Metabolism (Wolters Kluwer)
- ConferenceLocate.com
- Diabetes & Vascular Disease Research (Sage)
- Diabetes in Control
- Endocrine Web
- Frontiers in Clinical Diabetes and Healthcare
- Healthcare Tech Outlook
- Journal of Diabetes
- MEDtube
- Nutrients
- PharmaVoice
- Physician’s Weekly
- Vessel Plus

FOR ADDITIONAL INFORMATION ON
Registration | Support | Exhibits
(818) 342-1889 | info@tmioa.com | www.WCIR.ORG
THE INTERNATIONAL COMMITTEE FOR INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES

CORPORATE SUPPORT

EMERALD LEVEL

ESPERION
AsahiKASEI
Abbott
Corcept
Boehringer Ingelheim
Lilly
FRACTYL

TOPAZ LEVEL

APPLIED THERAPEUTICS

UNRESTRICTED EDUCATIONAL GRANT

BAYER
ASTRAZENECA
PFIZER / MERCK ALLIANCE
ZEALAND PHARMA
NOVO NORDISK
AMARIN PHARMA